Given the critical role and the broad impact of the NO-sGC-cGMP pathway on vasculature and on multiple organ systems in health and disease, sGC stimulators have been investigated for cardiovascular cardiorenal and cardiopulmonary disease therapy [34, 35, 37–39]. This evidence concerns the gene SGCB and cor pulmonale.